Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ATLCAR.CD30.CCR4 cells |
Synonyms | |
Therapy Description |
ATLCAR.CD30.CCR4 cells are autologous T-lymphocytes that are engineered to express CCR4 linked to a chimeric antigen receptor that recognizes CD30 and the co-stimulatory domains of CD28 and CD3zeta, which potentially results in increased immune response against CD30-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATLCAR.CD30.CCR4 cells | ATLCAR.CD30-CD28zeta-CCR4 cells | ATLCAR.CD30.CCR4 cells are autologous T-lymphocytes that are engineered to express CCR4 linked to a chimeric antigen receptor that recognizes CD30 and the co-stimulatory domains of CD28 and CD3zeta, which potentially results in increased immune response against CD30-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03602157 | Phase I | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Recruiting | USA | 0 |